Thread by @drdonsdizon

This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22

This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22

Retrospective study suggests bevacizumab + chemo improved survival in people with ovarian clear cell carcinoma. Hypothesis generating for sure.
This study was a larger retrospective in Japan before and after Bev was approved.

This is a very small study

Study cohort characteristics: Noted that 30% of those with ovarian clear cell cancer experienced thrombosis.

Chemo schedule was different; may have an impact on results.

Retrospective study survival results:
Median PFS 30 vs 12m (bev used vs no bev)

Subgroup analysis interesting in lack of evidence that few specific criteria favored use of Bev

Two cents: not level 1 data. confounders make it difficult to interpret. Biases hard to account for in such a small number of patients treated. Enough to go to a phase 3 trial for sure, if there was an appetite to launch one...